Overview
Lobbying Costs
250,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
0.5 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Grünenthal GmbH (Grünenthal)
EU Transparency Register
67826544528-01 First registered on 14 Nov 2010
Goals / Remit
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain.
As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to people living with pain worldwide. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. We’re a fully integrated pharmaceutical company that offers support along the entire value chain – from drug development through to commercialisation.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are sold in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of € 1.3 billion.Main EU files targeted
Grünenthal interests in Brussels deal with issues related to health- and pain care, pharmaceuticals, innovation, research and intellectual property.
Address
Head Office
Zieglerstraße, 6
Aachen D-52099
GERMANYEU Office
S.A. Grünenthal N.V.
Lenneke Marelaan 8
Sint-Stevens-Woluwe 1932
BELGIUM -
People
Total lobbyists declared
1
Employment time Lobbyists 50% 1 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 04 Feb 2020
Name Start date End Date Ms Gudula Maria Petersen 14 Jun 2018 14 Jun 2019 Mr Theodorus Norbertus Maria van Rooij 17 Oct 2017 17 Oct 2018 Ms Gudula Maria Petersen 12 May 2017 09 May 2018 Mr Theodorus Norbertus Maria van Rooij 10 Oct 2016 05 Oct 2017 Ms Gudula Maria Petersen 29 Apr 2016 29 Apr 2017 Mr Theodorus Norbertus Maria van Rooij 24 Sep 2015 19 Sep 2016 Mr Konrad Labuschagne 21 May 2014 05 Jun 2015 Mr Konrad Labuschagne 25 May 2013 21 May 2014 Mrs Kristina Barinka 02 Mar 2013 29 Mar 2014 Mr Konrad Labuschagne 19 Jun 2012 17 Jun 2013 Mr Theodorus Norbertus Maria van Rooij 24 Mar 2012 01 Dec 2012 Mrs Kristina Barinka 24 Mar 2012 01 Dec 2012 Complementary Information
In 2015 0,5 FTE
In 2016 0,75 FT
In 2017 0,75 FT
In 2018 0,5 FT
In 2019 0,5 FTPerson in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA): http://www.efpia.eu as well as of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): https://www.ifpma.org/ and has signed their respective codes.
Grünenthal is a partner in the Societal Impact of Pain (SIP) platform. More info can be found here: https://www.sip-platform.euMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
250,000€
Other financial info
The estimate of the annual costs related to activities covered by the register is based on a percentage of the salaries of the staffers in 2018 falling under the scope of the register, based on the proportion of employee time spent on these activities.
Furthermore we have included consultancy costs, member association fees and support of health policy related activities in Brussels. -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
Grünenthal is dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital.
You find an overview of our initiatives here: https://www.grunenthal.com/about-us/initiativesOther activities
In 2019 Grunenthal was partner in the Societal Impact of Pain (SIP) platform.
The scientific framework of the SIP platform is under the responsibility of the European Pain Federation EFIC®. Co-operation partners for SIP are Pain Alliance Europe and Active Citizenship Network. The pharmaceutical company Grünenthal GmbH is responsible for funding and non-financial support.- Meetings
Meetings
None declared
- Meetings